Having navigated the challenge of running a clinical trial during a global pandemic, Destiny has blossomed in mid-2020. It is on track to announce topline Phase 2b results for XF-73 in the prevention of post-surgical infections in Q1 2021. It has also expanded its pipeline to span the two most contemporary issues in biotech – the microbiome and the prevention of COVID-19 infections. Destiny’s interim financials demonstrate its continued prudent financial management that underpins these achievements against the backdrop of Covid-19.
17 Sep 2020
Plenty of progress in H1
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Plenty of progress in H1
Destiny Pharma Plc (DEST:LON) | 21.2 0.4 10.4% | Mkt Cap: 20.3m
- Published:
17 Sep 2020 -
Author:
Andy Smith -
Pages:
4
Having navigated the challenge of running a clinical trial during a global pandemic, Destiny has blossomed in mid-2020. It is on track to announce topline Phase 2b results for XF-73 in the prevention of post-surgical infections in Q1 2021. It has also expanded its pipeline to span the two most contemporary issues in biotech – the microbiome and the prevention of COVID-19 infections. Destiny’s interim financials demonstrate its continued prudent financial management that underpins these achievements against the backdrop of Covid-19.